Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment

Journal of Pharmacological and Toxicological Methods

Volumn 53, Issue 1, 2006, Pages 11-19

  Tattersall, Marshall Leslie ^a   Dymond, Michael ^a   Hammond, Tim ^a   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Animal models; Cardiovascular system; Electrocardiogram; Heart rate; QT interval; QTc interval; Safety pharmacology

Indexed keywords

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART RATE; HEART REPOLARIZATION; LINEAR REGRESSION ANALYSIS; MALE; NONHUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; RR INTERVAL; SEX DIFFERENCE; STATISTICAL MODEL; TOXICITY TESTING;

ANIMALS; ATRIOVENTRICULAR NODE; BUNDLE OF HIS; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; LONG QT SYNDROME; MALE; MODELS, ANIMAL; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 30144442919     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2005.02.005     Document Type: Article

References (30)

1. N. Abi-Gerges, K. Philp, C. Pollard, I.D. Wakefield, T.G. Hammond, and J.P. Valentin Gender differences in ventricular repolarization: From cardiac electrophysiology to torsades de pointes Fundamental and Clinical Pharmacology 18 2 2004 139 151
2. Anon Guidance for industry: Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals (M3) 1997 US Department of Health and Human Services, Food and Drug Administration
3. Anon. (1997b). Points to consider in the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. http://www.emea.eu.int/pdfs/human/swp/098696en.pdf
4. Anon. (2000). ICHS7A Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00. http://www.emea.eu.int/pdfs/human/ich/ 053900en.pdf
5. H.C. Bazett An analysis of the time relationships or time-relations of electrocardiograms Heart 7 1920 353 380
6. A.S. Davis, and B.J. Middleton Relationship between QT interval and heart rate in Alderley Park Beagles The Veterinary Record 145 1999 248 250
7. F. De Ponti, E. Poluzzi, and N. Montanaro QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience European Journal of Clinical Pharmacology 56 2000 1 18
8. D.K. Detweiler The use of electrocardiography in toxicological studies with Beagle dogs T. Balasz Cardiac toxicology vol. III 1985 CRC Press Boca Raton, Florida 34 82
9. M.F.W. Festing, P. Overend, R. Gaines Das, M. Cortina Borja, and M. Berdoy Laboratory animal handbooks The design of animal experiments vol. 14 2002 71 83 Published for Laboratory Animals Ltd by Royal Society of Medicine Press Ltd
10. L.S. Fridericia Die sytolendauer in elektrokardiogramm bei normalen menschen und bei herzkranken Acta Medica Scandinavica 53 1920 469 505
11. A.A. Fossa, M.J. Depasquale, D.L. Raunig, M.J. Avery, and D.J. Leishman The relationship of clinical QT prolongation to outcome in the conscious dog using a beat to beat QT-RR interval assessment Journal of Pharmacological and Experimental Therapeutics 202 2002 828 833
12. P. Greaves, A. Williams, and M. Eve First dose of potential new medicines to humans: How animals help Nature Reviews/Drug Discovery 3 2004 226 236
13. R.L. Hamlin, A. Kijtawornrat, and B.W. Keene How many cardiac cycles must be measured to permit accurate RR, QT, and QTc estimates in conscious dogs? Journal of Pharmacological and Toxicological Methods 50 2004 103 108
14. T.G. Hammond, L. Calsson, A.S. Davis, W.G. Lynch, I. MacKenzie, and W.S. Redfern Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey Cardiovascular Research 49 2001 741 750
15. G. Hanton, K. Nahas, C. Priou, Y. Rabemampianina, and P. Baneux The QT interval in the dog ECG: Importance in preclinical toxicology and relationship to heart rate Toxicology Methods 11 2001 21 40
16. W. Haverkamp, G. Breithardt, A.J. Camm, M.J. Janse, M.R. Rosen, and C. Antzelevitch The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology Cardiovascular Research 47 2000 219 233
17. D. Hunter, J. Schofield, K. Gracie, J. Moors, K. Philp, and P. Carter Use of a non-invasive telemetry system (EMKA) for functional cardiovascular endpoints in toxicology studies Journal of Pharmacological and Toxicological Methods 49 2004 234
18. D. Hunter, J. Schofield, K. Gracie, J. Moors, K. Philp, and H. Prior Comparisons of a non-invasive versus invasive dog telemetry Journal of Pharmacological and Toxicological Methods 49 2004 234
19. S. Ishida, M. Nakagawa, T. Fujimo, H. Yonemochi, T. Saikawa, and M. Ito Circadian variation of QT interval dispersion: Correlation with heart rate variability Journal of Electrocardiology 30 3 1997 205 210
20. K.T. Lee, W.T. Lai, C.S. Chu, H.M. Su, H.W. Yen, and W.C. Voon Circadian variation of QT dispersion determined by twelve-lead Holter electrocardiography Cardiology 100 2 2003 101 102
21. T. Matsunaga, T. Mitsui, T. Harada, M. Inokuma, H. Murano, and Y. Shibutani QT corrected for heart rate and relationship between QT and RR intervals in Beagle dogs Journal of Pharmacological and Toxicological Methods 38 1997 201 209
22. J.A. Moss The QT interval and Torsade de Pointes Drug Safety 21 Supp 1 1999 5 10
23. H. Olson, G. Betton, J. Stritar, and D. Robinson The predictivity of the toxicity of pharmaceuticals in humans from animal data-an interim assessment Toxicology Letters 102-103 1998 535 538
24. B.D. Osborne, and G.D.H. Leach The Beagle electrocardiogram Food and Cosmetics Toxicology 9 1971 857
25. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, and S. Palethorpe Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development Cardiovascular Research 58 2003 32 45
26. A. Sagie, M.G. Larson, R.J. Goldberg, J.R. Bengtson, and D. Levy An improved method for adjusting the QT interval for heart rate (the Framingham heart study) American Journal of Cardiology 70 1992 797 801
27. S. Spence, K. Soper, C.M. Hoe, and J. Coleman The heart rate-corrected QT interval of conscious Beagle dogs: A formula based on analysis of covariance Toxicological Sciences 45 1998 247 258
28. H. Todt, G. Krumpl, K. Krejcy, and G. Raberger Mode of QT correction for heart rate: Implications for the detection of inhomogeneous repolarization after myocardial infarction American Heart Journal 124 3 1992 602 609
29. J.-P. Valentin, M. Dymond, M.L. Tattersall, and T.G. Hammond Correction of QT duration values to allow for changes in heart rate in conscious Beagle dogs Fundamental and Clinical Pharmacology 15 7P101 2001 28
30. A. Van de Water, J. Verheyen, R. Xhonneux, and R.S. Reneman An improved method to correct the QT interval of the electrocardiogram for changes in heart rate Journal of Pharmacological Methods 22 1989 207 217